A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib

Combination cediranib/olaparib has reported activity in relapsed ovarian cancer. This phase 2 trial investigated the activity of cediranib/olaparib in relapsed ovarian cancer and its association with homologous recombination deficiency (HRD). Seventy patients were enrolled to cohorts of either plati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2024-08, Vol.187, p.105-112
Hauptverfasser:	Liu, Joyce F., Xiong, Niya, Wenham, Robert M., Wahner-Hendrickson, Andrea, Armstrong, Deborah K., Chan, Nancy, O'Malley, David M., Lee, Jung-Min, Penson, Richard T., Cristea, Mihaela C., Abbruzzese, James L., Matsuo, Koji, Olawaiye, Alexander B., Barry, William T., Cheng, Su-Chun, Polak, Madeline, Swisher, Elizabeth M., Shapiro, Geoffrey I., Kohn, Elise C., Ivy, S. Percy, Matulonis, Ursula A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Anti-angiogenic Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Ovarian Epithelial - drug therapy Carcinoma, Ovarian Epithelial - genetics Cediranib Drug Resistance, Neoplasm - genetics Female Homologous Recombination Humans Indoles Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - pathology Olaparib Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology PARP inhibitor Phthalazines - administration & dosage Piperazines - administration & dosage Progression-Free Survival Quinazolines - administration & dosage Quinazolines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!